Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Yazun Jarrar"'
Publikováno v:
Endocrine, Metabolic & Immune Disorders - Drug Targets. 23:375-387
Background: Diabetes Mellitus (DM) is considered the fourth leading cause of death in Palestine, with a prevalence of 9.1% in patients aged 20–79 years, and is predicted to increase to 20.6% by 2020. Aims: This study aims to estimate DM costs, comp
Publikováno v:
Endocrine, Metabolic & Immune Disorders - Drug Targets. 21:464-471
Background: Diabetes prevalence at Palestine was 10%, with a rising fund crisis, and diabetes healthcare problems. There was a limited research concerning diabetes healthcare dimensions including organizational factors and their predictors. Objective
Publikováno v:
Endocrine, Metabolic & Immune Disorders - Drug Targets. 22
Background: COVID-19 is a new pandemic and the best protection against this infection is by vaccination. Aims: To assess the commitment to COVID-19 health precautions and vaccination willingness among the Palestinian population. Methods: An online-ba
Publikováno v:
Endocrine, Metabolic & Immune Disorders - Drug Targets. 21:352-359
Background: Endothelial nitric oxide synthase (eNOS) plays a major role in the response of anti-hypercholesterol statin drugs. Genetic polymorphisms in the eNOS gene affect the activity of eNOS thereby modulating the statin response. Objectives: This
Publikováno v:
Endocrine, Metabolic & Immune Disorders - Drug Targets. 20:895-902
Background: The Human Leukocyte Antigen (HLA) class II genes, particularly the HLADR and -DQ loci, have been shown to play a crucial role in Type 1 Diabetes (T1D) development. Objective: This study is the first to examine the contribution of the HLA-
Autor:
Wajdy Al-Awaida, Farah Al Madhoon, Yazun Jarrar, Hamzeh J Al-Ameer, Raida Khalil, Rand Qawadri, Loiy Obeidat, Amer Imraish, Omar Al bawareed
Publikováno v:
Endocrine, metabolicimmune disorders drug targets. 21(10)
Background: Fibromyalgia syndrome (FMS) is a chronic disease characterized by widespread body pain, weakness in certain parts of the body (critical points), low pain tolerance, sleep disturbances, and fatigue. This syndrome is considered rare in Jord
Autor:
Bashir M. Jarrar, Ali A. Shati, Yazun Jarrar, Mohammed A. Al-Kahtani, Amin A Al-Doaiss, Mohammad Y. Alfaifi
Publikováno v:
Endocrine, metabolicimmune disorders drug targets. 21(11)
Background: Atorvastatin (ATOR) is widely used for the treatment and prevention of hypercholesterolemia and various diseases, such as cardiovascular complication, with little data about the histopathological and ultrastructural renal alterations that